Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: MPN Clear all
Recruiting Phase 1Phase 2 Interventional

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

NCT06523556
View directory record Official record
Conditions
Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myeloproliferative Neoplasm
Interventions
Axatilimab, Azacitidine, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Survey Administration
Biological · Drug · Procedure + 1 more
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Terminated Phase 2 Interventional Results available

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

NCT00726232
View directory record Official record
Conditions
Myeloproliferative Neoplasm (MPN)
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 6, 2026, 4:56 PM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

NCT05600894
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Venetoclax
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Costa Mesa, California • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Recruiting Phase 1Phase 2 Interventional

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

NCT04061421
View directory record Official record
Conditions
MDS/MPN
Interventions
ASTX727, Itacitinib, Ruxolitinib
Drug
Lead sponsor
Michael Savona
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Tampa, Florida • Rochester, New York • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Recruiting Phase 1 Interventional

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

NCT04771572
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase
Interventions
LP-118
Drug
Lead sponsor
Newave Pharmaceutical Inc
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Chicago, Illinois • Boston, Massachusetts • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Completed No phase listed Observational

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

NCT02953704
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Not listed
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
114
States / cities
Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Sep 6, 2026, 4:56 PM EDT
Recruiting Phase 1 Interventional

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

NCT05025488
View directory record Official record
Conditions
Myelofibrosis, Essential Thrombocythemia, MPN
Interventions
Peptide-based vaccine, Poly ICLC
Drug
Lead sponsor
Marina Kremyanskaya
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 6, 2026, 4:56 PM EDT
Terminated Phase 2 Interventional Results available

Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

NCT04103645
View directory record Official record
Conditions
Myeloproliferative Neoplasm
Interventions
Vactosertib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

NCT02492737
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies
Interventions
AG881
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

NCT02493530
View directory record Official record
Conditions
Myelofibrosis, Polycythemia Vera
Interventions
TGR-1202, ruxolitinib
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Phoenix, Arizona • Aurora, Colorado • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Terminated Phase 1 Interventional

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

NCT05609942
View directory record Official record
Conditions
Advanced Systemic Mastocytosis
Interventions
BLU-263, Azacitidine
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

NCT00952289
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Ruxolitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
88
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Baldwin Park, California + 85 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 6, 2026, 4:56 PM EDT
Terminated Phase 1 Interventional Results available

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

NCT02663518
View directory record Official record
Conditions
Hematologic Malignancies, Solid Tumor
Interventions
PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
47
States / cities
Duarte, California • Palo Alto, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies

NCT01606579
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Interventions
PRI-724
Drug
Lead sponsor
Prism Pharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Worcester, Massachusetts • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)

NCT03140280
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Freeze-Dried Black Raspberry Powder
Drug
Lead sponsor
Ehab L Atallah
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 6, 2026, 4:56 PM EDT
Recruiting Phase 2 Interventional

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

NCT05835466
View directory record Official record
Conditions
Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Interventions
reparixin
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Active, not recruiting Phase 3 Interventional

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

NCT04285086
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Ropeginterferon alfa-2b, Anagrelide
Biological · Drug
Lead sponsor
PharmaEssentia
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
4
States / cities
Scottsdale, Arizona • St Louis, Missouri • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

NCT03011372
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Pemigatinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
9
States / cities
Phoenix, Arizona • Duarte, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 6, 2026, 4:56 PM EDT
Terminated Phase 1 Interventional

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

NCT05524857
View directory record Official record
Conditions
Myeloproliferative Neoplasm
Interventions
Fedratinib Oral Capsule 300 mg, Decitabine 20 mg/m2, Fedratinib Oral Capsule 400 mg
Drug
Lead sponsor
Joseph Jurcic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 6, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

NCT00621504
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 6, 2026, 4:56 PM EDT
Completed No phase listed Observational

MPN Podcast Pilot Study

NCT03907774
View directory record Official record
Conditions
Myeloproliferative Neoplasm, Unclassifiable
Interventions
Not listed
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 6, 2026, 4:56 PM EDT
Recruiting Early Phase 1 Interventional

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

NCT04187703
View directory record Official record
Conditions
Myelodysplastic Syndromes, MDS/MPN Crossover Syndromes
Interventions
5-azacytidine, Decitabine
Drug
Lead sponsor
Benjamin Tomlinson
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

NCT07469891
View directory record Official record
Conditions
Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Primary Myelofibrosis (PMF)
Interventions
PRT12396
Drug
Lead sponsor
Prelude Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Denver, Colorado • Coral Springs, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 6, 2026, 4:56 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 6, 2026, 4:56 PM EDT